Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab)

INTRODUCTION: PF-06438179, a potential biosimilar to Remicade(®) (infliximab, Janssen Biotech, Inc.), is a chimeric mouse–human monoclonal antibody targeting human tumor necrosis factor alpha (TNF). METHODS: Analytical (small subset reported here) and nonclinical studies compared the structural, fun...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Adv Ther
Päätekijät: Derzi, Mazin, Johnson, Theodore R., Shoieb, Ahmed M., Conlon, Hugh D., Sharpe, Penny, Saati, Andrew, Koob, Sarah, Bolt, Michael W., Lorello, Leslie G., McNally, Jim, Kirchhoff, Carol F., Smolarek, Teresa A., Leach, Michael W.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Healthcare 2016
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5083783/
https://ncbi.nlm.nih.gov/pubmed/27585978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-016-0403-9
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia